Brivaracetam (UCB 34714)

Neurotherapeutics

Volumn 4, Issue 1, 2007, Pages 84-87

  von Rosenstiel, Philipp ^a  

^a UCB   (Belgium)

Author keywords

Brivaracetam; SV2A; synaptic vesicle protein 2A; UCB 34714

Indexed keywords

ANTICONVULSIVE AGENT; BRIVARACETAM; CARBAMAZEPINE; CARBAMAZEPINE 10,11 OXIDE; DIAZEPAM; ETIRACETAM; ORAL CONTRACEPTIVE AGENT; PHENYTOIN; PROTEIN; SODIUM CHANNEL; SYNAPTIC VESICLE PROTEIN 2A; UNCLASSIFIED DRUG;

ABSENCE; ANTICONVULSANT ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; CARCINOGENICITY; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CLONIC SEIZURE; CONVULSION; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; ELECTROENCEPHALOGRAM; EPILEPSY; EPILEPTIC DISCHARGE; EPILEPTIC STATE; FETUS DEVELOPMENT; FOCAL EPILEPSY; GASTROINTESTINAL ABSORPTION; GASTROINTESTINAL SYMPTOM; GENETIC SUSCEPTIBILITY; GENOTOXICITY; HEPATOBILIARY DISEASE; HIPPOCAMPUS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFERTILITY; KIDNEY CLEARANCE; KIDNEY FUNCTION; LIVER FAILURE; LOW DRUG DOSE; NEUROTOXICITY; NONHUMAN; PHOTOSENSITIVE EPILEPSY; PRIORITY JOURNAL; REPEATED DRUG DOSE; RESPIRATORY TRACT DISEASE; SEIZURE; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE;

ANIMALS; ANTICONVULSANTS; BRAIN; CLINICAL TRIALS; EPILEPSY; HUMANS; PYRROLIDINONES;

EID: 33846204772     PISSN: 19337213     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nurt.2006.11.004     Document Type: Article

References (14)

1. Crowder K.M., Gunther J.M., Jones T.A., Hale B.D., Zhang H.Z., Peterson M.R., et al. Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A). Proc Natl Acad Sci 96 (1999) 15268-15273
2. Lynch B., Lambeng N., Nocka K., et al. The Synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci 101 (2004) 9861-9866
3. Kenda B.M., Matagne A.C., Talaga P.E., Pasau P.M., Differding E., Lallemand B.I., et al. Discovery of 4-substituted pyrrolidone butanamides as new agents with significant antiepileptic activity. Journal of Medicinal Chemistry 47 (2004) 530-549
4. +-currents in rat cortical neurons in culture. Epilepsia 45 suppl 7 (2004) 146
5. Margineanu D.-G., Kenda B.M., Michel P., Matagne A.C., and Klitgaard H. ucb 34714, a new pyrrolidone derivative: comparison with levetiracetam in hippocampal slice epilepsy models in vitro. Epilepsia 44 suppl 9 (2003) 261
6. Margineanu D.-G., and Klitgaard H. Inhibition of neuronal hypersynchrony in vitro differentiates levetiracetam from classical antiepileptic drugs. Pharmacol Res 42 (2000) 281-285
7. Matagne A.C., Kenda B.M., Michel P., and Klitgaard H. 2003. ucb 34714, a new pyrrolidone derivative: comparison with levetiracetam in animal models of chronic epilepsy in vivo. Epilepsia 44 suppl 9 (2003) 260
8. Mazarati A.M., Wasterlain C.G., Sankar R., and Shin D. 1998. Self-sustaining status epilepticus after brief electrical stimulation of the perforant path. Brain Res 801 (1998) 251-253
9. Mazarati A.M., Baldwin R.A., Sankar R., and Wasterlain C.G. Time-dependent decrease in the effectiveness of antiepileptic drugs during the course of self-sustaining status epilepticus. Brain Res 14 (1998) 179-185
10. Wasterlain C.G., Suchomelova L., Matagne A.C., Klitgaard H., Mazarati A.M., Shinmei S., et al. Brivaracetam is a potent anticonvulsant in experimental status epilepticus. Epilepsia 46 suppl 8 (2005) 219
11. Rolan P., Pigeolet E., and Stockis A. Ucb 34714: single and multiple rising dose safety, tolerability, and pharmacokinetics in healthy subjects. Epilepsia 45 suppl 7 (2004) 314-315
12. Sargentini-Maier M.L., Rolan P., Connell J., et al. Brivaracetam safety, tolerability, pharmacokinetics and CNS pharmacodynamic effects after 10 to 1400 mg single rising oral doses in healthy males. Br J Clin Pharmacol (2006) (in press)
13. Potter J.M., and Donnelly A. Carbamazepine-10,11-Epoxide in Therapeutic Drug Monitoring. Ther Drug Monit 20 (1998) 652-657
14. Kasteleijn-Nolst Trenité D.G.A., Parain D., Masnou P., Genton P., Steinhoff J., and Hirsch E. Proof of principle in the new AED ucb 34714: use of the photosensitivity model. Epilepsia 45 suppl 7 (2004) 309